Natural immunity and protection against variants in South African children through five COVID-19 waves: A prospective study

Int J Infect Dis. 2024 Nov 13:107300. doi: 10.1016/j.ijid.2024.107300. Online ahead of print.

Abstract

Background: Children have been largely spared from serious disease through the COVID-19 pandemic despite high exposure to SARS-CoV-2. Antibody responses to exposure and their role in protecting children from subsequent variant infection remains poorly understood.

Methods: A prospective cohort study of children in a South African community through ancestral/Beta/Delta/Omicron BA.1/BA.2 and BA.4/BA.5 SARS-CoV-2 waves (March 2020-October 2022). Health seeking behaviour/illness was recorded and post-wave serum samples measured for IgG to Spike (CoV2-S-IgG) by ECLIA. To estimate protective CoV2-S-IgG threshold levels, logistic functions were fit to describe the correlation of CoV2-S-IgG measured before a wave and the probability for seroconversion/boosting thereafter.

Findings: Despite little disease 125/366 (34·2%) children (median age 6·7y (IQR 5.9·9 7·4y) were seropositive following wave 1, rising to 53·6%, 76·0%, 96·2% and 99·2% after waves 2 (Beta), 3 (Delta), 4 and 5 (Omicron variants) respectively. CoV2-S-IgG induced by natural exposure protected against subsequent SARS-CoV-2 infection with the greatest protection for Beta and least for Omicron. Levels of IgG specific for ancestral spike (S) antigen that provided a 50% protective threshold for the subsequent wave were lowest for the Beta and highest for the Omicron BA.1/BA.2 wave. In multivariate analysis, maternal seropositivity (aOR=2·57 (95% CI: 1·72; 3·82) was strongly associated with child seropositivity.

Interpretation: Children responded robustly to successive waves of SARS-CoV-2 mounting IgG responses to spike antigen that were protective against subsequent waves. In the absence of vaccination almost all children were seropositive after the 5th wave but none were hospitalised suggesting natural immunity alone may be sufficient to protect children in a pandemic setting.

Funding: UK NIH GECO award (GEC111), Wellcome Biomedical resources grant (221372/Z/20/Z), Wellcome Trust Centre for Infectious Disease Research in Africa (CIDRI), Bill & Melinda Gates Foundation, USA (OPP1017641, OPP1017579) and NIH H3 Africa (U54HG009824, U01AI110466]. HZ is supported by the SA-MRC. MPN is supported by an Australian National Health and Medical Research Council Investigator Grant (APP1174455). BJQ is supported by a grant from the Bill and Melinda Gates Foundation (OPP1139859). Stefan Flasche is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant number 208812/Z/17/Z).

Keywords: African; COVID-19; SARS-CoV-2; antibodies; child; immunity; mother; protective threshold; vaccination; variant.